TriSalus Life Sciences IncNASDAQ:TLSI
- LAST PRICE4.1400
- TODAY'S CHANGE (%)-0.3900 (-8.6093%)
- Bid / Lots4.1300/ 1
- Ask / Lots4.1500/ 4
- Open / Previous Close4.6500 / 4.5300
- Day Range
- 52 Week Range
- Volume53,399
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSI |
|---|---|---|
| 09:32 ET | 331 | 4.65 |
| 09:37 ET | 215 | 4.64 |
| 10:04 ET | 1300 | 4.56 |
| 10:09 ET | 1300 | 4.52 |
| 10:11 ET | 1330 | 4.52 |
| 10:24 ET | 5219 | 4.35 |
| 10:42 ET | 1200 | 4.29 |
| 10:47 ET | 100 | 4.27 |
| 10:49 ET | 651 | 4.28 |
| 10:51 ET | 400 | 4.26 |
| 10:54 ET | 500 | 4.25 |
| 10:56 ET | 550 | 4.25 |
| 11:00 ET | 24900 | 4.22 |
| 11:02 ET | 415 | 4.23 |
| 11:03 ET | 100 | 4.22 |
| 11:07 ET | 100 | 4.22 |
| 11:12 ET | 447 | 4.19 |
| 11:16 ET | 858 | 4.255 |
| 11:36 ET | 2353 | 4.21 |
| 11:38 ET | 2431 | 4.12 |
| 11:45 ET | 482 | 4.2892 |
| 11:57 ET | 250 | 4.28 |
| 11:59 ET | 250 | 4.2732 |
| 12:06 ET | 1025 | 4.21 |
| 12:21 ET | 1800 | 4.17 |
| 12:39 ET | 451 | 4.17 |
| 12:55 ET | 200 | 4.175 |
| 02:21 ET | 400 | 4.165 |
| 02:25 ET | 120 | 4.18 |
| 02:45 ET | 775 | 4.14 |
Nov 15, 2024
DJ TriSalus Life Sciences Is Maintained at Buy by Canaccord Genuity, from 9:37AM ET on Friday Nov 15, 2024 by Dow Jones
9:37AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
TriSalus Reports Q3 2024 Financial Results and Provides Business Update, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: TriSalus Reports Q3 2024 Financial Results and Provides Business Update, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 11, 2024
DJ TriSalus Life Sciences Initiated at Buy by Roth MKM, from 7:09AM ET on Monday Nov 11, 2024 by Dow Jones
7:09AM ET on Monday Nov 11, 2024 by Dow JonesTriSalus Life Sciences(R) Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav(R) Infusion System to U.S. Veterans with Liver Cancer, from 7:00AM ET on Monday Nov 11, 2024 by Dow Jones
7:00AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TriSalus Life Sciences Inc | 132.8M | -2.5x | --- |
Fennec Pharmaceuticals Inc | 145.9M | -56.7x | --- |
Adagene Inc | 97.1M | -3.1x | --- |
Elutia Inc | 142.4M | -2.0x | --- |
Mediwound Ltd | 177.8M | -8.0x | --- |
Cellectis SA | 130.3M | -1.3x | --- |
Company Information
TriSalus Life Sciences, Inc. is an oncology focused medical technology business providing drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. Its two Food and Drug Administration (FDA) cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. Additionally, the Company is exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications.
Contact Information
- Headquarters
- 6272 W. 91st Ave.WESTMINSTER, CO, United States 80031
- Phone
- 415-336-8917
- Fax
- 302-636-5454
Executives
- Independent Non-Executive Chairman of the Board
- Mats Wahlstrom
- President, Chief Executive Officer, Director
- Mary Szela
- Chief Financial Officer, Director
- Sean Murphy
- President - Commercial Operations
- Jodi Devlin
- Senior Vice President - Investor Relations, Treasurer
- James Young
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $132.8M |
|---|---|
Revenue (TTM) | $26.9M |
Shares Outstanding | 29.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.54 |
EPS | $-1.68 |
Book Value | $-0.98 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -158.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
